CSL112 is an apolipoprotein A1 (apoA-I) derived from human plasma, and is a component of high-density lipoprotein (known as the “good” cholesterol). CSL112 removes plaque from the arteries, and helps facilitate cholesterol efflux, the removal process of low-density lipoprotein (known as the “bad” cholesterol) from the body.
The AEGIS-II trial determined that CSL112, when compared to placebo, did not significantly lower the risk of patients experiencing recurrent cardiovascular (CV) events following an acute myocardial infarction (MI), commonly known as a heart attack. In a recently published exploratory analysis of the AEGIS-II trial in the Journal of the American College of Cardiology, researchers (including Drs. Shaun Goodman and Kevin Bainey from the CVC) sought to evaluate the impact of CSL112 therapy on the occurrence of CV death and recurrent MI.
AEGIS-II enrolled a total of 18,219 patients with acute MI, multivessel coronary artery disease, and additional cardiovascular risk factors (e.g., diabetes), who were randomly assigned in a 1:1 ratio to receive either 6 g of CSL112 or a matching placebo through 4 weekly infusions. Although CSL112 did not significantly reduce the risk of recurrent CV events, the exploratory analysis found that patients treated with CSL112 infusions had numerically lower rates of CV death and MI (primarily spontaneous MI and MI from stent thrombosis). These findings indicate that apoA-I could potentially play a role in lessening the risk of future plaque disruption through the process of enhanced cholesterol efflux. The study authors emphasize the need for further research, including randomized clinical trials, in order to expand upon and confirm these findings.
